TG Therapeutics Inc. (TGTX)
NASDAQ: TGTX
· Real-Time Price · USD
32.21
0.32 (1.00%)
At close: Sep 05, 2025, 3:59 PM
32.30
0.28%
After-hours: Sep 05, 2025, 07:56 PM EDT
TG Therapeutics Revenue Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|
| License Revenue Revenue | 38K | 76K | 38K | 38K | 38K | 66.94M | 25.07M | 1.51M | 755K |
| License Revenue Revenue Growth | -50.00% | +100.00% | 0.00% | 0.00% | -99.94% | +167.02% | +1563.44% | +99.60% | n/a |
| Other Revenue Revenue | 558K | 1.09M | 315K | 682K | 415K | n/a | n/a | n/a | n/a |
| Other Revenue Revenue Growth | -48.95% | +246.98% | -53.81% | +64.34% | n/a | n/a | n/a | n/a | n/a |
| Product Revenue | 119.66M | 179.94M | 83.3M | 72.6M | 50.49M | n/a | n/a | n/a | n/a |
| Product Revenue Growth | -33.50% | +116.03% | +14.74% | +43.79% | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue | 605K | 539K | 229K | 150K | 33K | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | +12.24% | +135.37% | +52.67% | +354.55% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 55.59M | 50.33M | 38.96M | 41.97M | 38.72M | 34.5M | 31.06M | 26.5M | 36.38M | 29.65M | 22.5M | 17.5M | 14.97M | 22.5M | 37.4M | 34.9M | 41.03M | 34.27M | 49.67M | 39.91M | 15.99M | 16.24M | 8.54M | 4.4M | 4.07M | 3.83M | 1.91M | 968K | 5.68M | 6.6M | 5.08M | 4.47M | 1.76M | 5.02M | 1.78M | 3.17M | 3.09M | 2.8M | 3.95M | 2.33M | 7.25M | 6.36M |
| Selling, General, and Administrative Revenue Growth | +10.44% | +29.18% | -7.16% | +8.39% | +12.23% | +11.07% | +17.21% | -27.16% | +22.69% | +31.76% | +28.57% | +16.95% | -33.50% | -39.83% | +7.16% | -14.95% | +19.72% | -31.00% | +24.44% | +149.67% | -1.56% | +90.07% | +94.36% | +8.06% | +6.19% | +100.37% | +97.52% | -82.97% | -13.85% | +29.95% | +13.47% | +154.64% | -65.01% | +181.69% | -43.69% | +2.29% | +10.54% | -29.16% | +69.95% | -67.91% | +13.93% | n/a |
| Research and Development Revenue | 31.78M | 46.36M | 23.87M | 20.14M | 17.56M | 32.72M | 17.45M | 11.84M | 22.46M | 14.29M | 29.64M | 17.55M | 24.55M | 46.15M | 57.66M | 51.97M | 37.85M | 55.58M | 37.15M | 45.85M | 34.9M | 34.04M | 29.45M | 56.5M | 31.51M | 30.9M | 51.07M | 32.75M | 37.81M | 32.16M | 25.74M | 25.33M | 25.44M | 20.38M | 21.41M | 20.88M | 12.97M | 11.23M | 13.73M | 11.54M | 9.9M | 8.28M |
| Research and Development Revenue Growth | -31.45% | +94.19% | +18.55% | +14.71% | -46.35% | +87.53% | +47.40% | -47.29% | +57.20% | -51.79% | +68.84% | -28.49% | -46.81% | -19.97% | +10.96% | +37.28% | -31.89% | +49.62% | -18.97% | +31.38% | +2.51% | +15.58% | -47.87% | +79.29% | +2.00% | -39.50% | +55.92% | -13.38% | +17.58% | +24.96% | +1.58% | -0.41% | +24.85% | -4.85% | +2.57% | +61.01% | +15.46% | -18.18% | +18.96% | +16.52% | +19.60% | n/a |